Menu

Recent Interviews

Lewis Black, CEO, Almonty Industries

Lewis Black
CEO | Almonty Industries
100 King Street West, M5X 1C7 Toronto (CAN)

info@almonty.com

+1 (647) 438-9766

Interview with mine operator Almonty Industries: "Tungsten makes e-cars better"


Nick Luksha, President, Prospect Ridge Resources

Nick Luksha
President | Prospect Ridge Resources
1288 West Cordova Street Suite 2807, V6C 3R3 Vancouver (CAN)

info@prospectridgeresources.com

Interview Prospect Ridge Resources: These fillets taste good to the market


Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


18. June 2020 | 08:40 CET

BioNTech, Evotec, EXMceuticals - which stocks have the potential to double?

  • Healthcare
Photo credits: pixabay.com

Experienced investors assume that the DAX, Germany's leading index, will still reach new highs in 2020. One of the best-known supporters of this scenario is the asset manager Dr. Jens Ehrhardt. Rising markets are supported by the measures taken by central banks and politicians - it is de facto the consequence of the increase in the money supply. This expected development will be of particular interest to those investors who have so far been on the sidelines and have to position themselves or reallocate.

time to read: 2 minutes by Mario Hose
ISIN: CA30207T1049 , US09075V1026 , DE0005664809


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Pessimists seldom have reason to be happy

At the stock exchange, buyer and seller meet. The buyer side sees potential, the seller side often has a different opinion. However, the motives for sales can also be detached from the question of the expected potential, for example, if the portfolio has become unbalanced or a stop-mark has been reached. Anyone who has been active on the stock market for a longer period of time and has been following the media closely has certainly already noticed that the optimists have reasons to be happy about a longer period and the pessimists can only ever feel confirmed in a relatively small but violent time window.

Central banks are pointing the way

For example, the DAX rose from 3,588 points in 2009 to 13,795 points in 2020 - a full 10,207 points. In the heat of the Corona battle, it went down to 8,255 points within four weeks starting in February, but at the current level of around 12,300 points, a new high is almost within reach again. The pessimists have now largely fallen silent again after their four-week celebration. The power of the central banks should not be underestimated.

Gateway to the EU market

If you want to participate in the future, you should take a look at EXMceuticals. The company signed a letter of intent last week with an operating subsidiary of Plena Global Holdings Inc, a major producer and supplier of medical grade cannabis ingredients. According to the agreement, the processing plant in Portugal planned by EXMceuticals will be supplied with GMP-compliant THC distillate in the future. With this agreement, EXMceuticals reinforces its strategy to position itself as the "gateway" to the European market for existing manufacturers of legal cannabis.

Europe as a growth market

"The demand will explode in the next few years as the European cannabis industry continues to develop into one of the largest cannabis markets in the world and more countries require the use of EU GMP standards. Securing valuable sources of ingredients with consistent, large-scale suppliers such as Plena Global is more important than ever for the buildout of the EXM supply chain. (...)," said Jonathan Summers, Chief Executive Officer of EXM.

Health in focus

BioNTech remains the focus of investors waiting for a vaccine against Covid-19. The team of experts cooperates with pharmaceutical giant Pfizer, among others. In addition, the company pursues the development of preparations and therapies for the individual treatment of cancer.

The active ingredient expert Evotec was also able to attract attention with positive reports in recent weeks. The company is participating in a project in the USA that is intended to enable the rapid assessment of potential health and environmental risks resulting from chemicals. In addition, a partnership was entered into for the development of antibodies against the immunodeficiency virus HIV. The US government has budgeted a volume of around USD 318 million for this project.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

15. October 2021 | 10:10 CET | by Nico Popp

MorphoSys, Sativa Wellness Group, CureVac: Healthcare investments of tomorrow

  • Healthcare

The healthcare sector is facing a reassessment. For years, especially in Germany, health care has been "fiddled with" - a reform here, a change there, but in basic terms, little has changed in the system in recent years. With the new federal government, things could start to move. Regardless of ideological trench warfare, observers can state, especially under the impression of the pandemic, that innovative treatment methods and preventive care are the most important trends for the future, along with the digitization of the healthcare system. In this context, we present three companies and highlight their opportunities.

Read

17. March 2021 | 07:25 CET | by Nico Popp

Fresenius SE, Q+M Dental Group, Siemens Healthineers: Where growth meets dividends

  • Healthcare

The back-and-forth surrounding AstraZeneca's vaccine has unsettled many people. But the discussion about extremely rare side effects also shows: Vaccines and drugs are subject to strict regulations and the healthcare system is strictly regulated. While pharmaceutical companies must always expect setbacks, especially in accelerated approval procedures, the situation is different for suppliers of medical technology or consumables. We present three stocks that are benefiting from rising healthcare spending.

Read

19. January 2021 | 10:50 CET | by Nico Popp

Pfizer, Q&M Dental Group, Johnson & Johnson: Where do profiteers of the pandemic lurk?

  • Healthcare

We all know that one's health is the most important thing. But from time to time, this truism slips out of focus. The pandemic has shown that neither fame nor money can protect you from getting sick. A big step toward being healthy, however, can be made by trusting in research. The development of vaccines in record time has shown how great the potential is in science and the pharmaceutical industry. New test methods are continually coming onto the market. Three shares show that there is money to be made on the stock market from these developments.

Read